The union government has approved Bharat Biotech's intranasal vaccine, iNCOVACC. It will be used as a heterologous booster & will be available first in private hospitals.

• It will be included in COVID vaccination program from today, official sources have told the media. 
• It is BBV154, novel adenovirus vectored, intranasal vaccine for COVID-19
• An intranasal vaccine stimulates a broad immune response – neutralizing IgG, mucosal IgA, and T cell responses, says Bharat Biotech.